NSRX Nasus Pharma Ltd
Price Chart
Executive Summary
Rubin Eyal, CFO and EVP of Nasus Pharma Ltd, filed a Form 3 disclosing ownership of unvested stock options for 126,197 ordinary shares. The options were granted on November 20, 2025, with an exercise price of $7.56 per share and expire on November 20, 2035. No shares were acquired or sold in this filing; it is a mandatory initial ownership report.
Actionable Insight
Monitor vesting dates—particularly November 20, 2026—for potential insider selling or exercise activity. Given the low exercise price relative to potential future valuation, this could become relevant in later-stage financing or exit scenarios.
Key Facts
- Form 3 filed by Rubin Eyal, CFO and EVP of Nasus Pharma Ltd, on March 27, 2026, reporting initial beneficial ownership.
- Two option grants disclosed: 85,648 options vesting starting February 27, 2027, and 40,549 options vesting fully on November 20, 2026.
- Total options: 126,197 ordinary shares at $7.56 exercise price, expiring November 20, 2035.
- As of March 18, 2026, none of the options are vested.
- No actual shares were bought or sold; this is a routine regulatory filing for initial ownership disclosure.
Financial Impact
No immediate financial impact. Potential future dilution of approximately 126,197 shares if fully exercised, representing about 0.48% of current market cap assuming $7.56 exercise price and $26M market cap.
Risk Factors
- Future share dilution if options are exercised.
- Potential insider selling pressure upon vesting, especially given the lack of current equity ownership disclosure.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001493152-26-013399 |
| Document: 0001493152-26-013399-index.html | 0001493152-26-013399 |
| Document: 0001493152-26-013399.txt | 0001493152-26-013399 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 1, 2026
10w ago
|
EFFECT
| $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $2.88 (−12.94%) |
|
Mar 28, 2026
11w ago
|
3
| $2.01 $2.91 | ▲ +44.78% | ▲ +32.18% | $2.88 (+43.28%) |
|
Mar 28, 2026
11w ago
|
3
| $2.01 $2.91 | ▲ +44.78% | ▲ +32.18% | $2.88 (+43.28%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $2.76 $3.40 | ▲ +23.19% | ▲ +15.33% | $2.88 (+4.35%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $3.10 $2.25 | ▼ −27.42% | ▼ −31.20% | $2.88 (−7.10%) |
|
Mar 16, 2026
13w ago
|
EFFECT
| $3.10 $2.25 | ▼ −27.42% | ▼ −31.20% | $2.88 (−7.10%) |
|
Mar 2, 2026
14w ago
|
F-1
| $4.75 $2.22 | ▲ +53.26% | ▲ +48.86% | $2.88 (+39.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access